The Pivotal ASC Evolution

Site-neutral payment isn't the win you think.

The 2026 OPPS rule moves Medicare further toward paying the same rate for the same procedure regardless of where it happens.

Hospital outpatient department. ASC. Same money.

Most of the ASC world is treating this as a victory.

Hospitals lose their premium. The field levels. Finally.

I read it differently.

The ASC value proposition for thirty years was partly clinical, partly operational, and partly arbitrage.

You did the same case for less, in a lower-cost setting, and the payment differential is what made the model work.

Site-neutral removes the differential.

When rates converge, "we cost less to run" stops being a pricing advantage and becomes just a margin.

And margin is an operating problem, not a policy one.

Your case mix. Your throughput. Your supply costs. Your staffing ratios. Your turnover time between cases.

That's a harder game.

It's also a better one, because it rewards operators instead of arbitrageurs.

But it will sort ASCs into two groups quickly.

The ones whose advantage was structural.

And the ones whose advantage was a rate gap they didn't create and can't defend.

If your model only works because of where the payment sits, rather than how you run the room, site-neutrality isn't a win.

It's a countdown.

When the rate differential goes away, what's actually left of your advantage?